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ABSTRACT. Novel pyrroles have been designed, synthesized and evaluated against 
mycobacterial strains. The pyrroles have originally been designed as hybrids of the anti-
tubercular drugs BM212 1 and SQ109 2 that showed common chemical features with very 
similar topological distribution. A perfect superposition of the structures of 1 and 2 revealed by 
computational studies suggested the introduction of bulky substituents at the terminal portion of 
the pyrrole C3 side chain and the removal of the C5 aryl moiety. Five compounds showed high 
activity toward Mycobacterium tuberculosis, while 9b and 9c were highly active also against 
multi-drug resistant clinical isolates. Compound 9c showed low eukaryotic cell toxicity, turning 
out to be an excellent lead candidate for preclinical trials. In addition, four compounds showed 
potent inhibition (comparable to that of verapamil) towards the whole-cell drug efflux pump 
activity of mycobacteria, and thus turning to be promising multi-drug resistance reversal agents. 
 
 
 
 
 
 
 INTRODUCTION 
Tuberculosis (TB) was first declared as a global health emergency by the World Health 
Organisation (WHO) in 1993. More than two decades on, the world is still grappling to control 
the spread of this infectious disease. In 2014, around 9.3 million people were estimated to have 
fallen ill with TB and 1.5 million deaths were caused by it.
1
 Although, mortality due to TB has 
fallen to 47% since 1990, the increasing resistance seen in the TB-causative organism, 
Mycobacterium tuberculosis (MTB), is responsible for new 480,000 estimated cases of 
multidrug-resistant TB. In fact, multi-, extensively- and even totally-drug resistant tuberculosis 
(MDR-,
2-4
 XDR-,
5-6
 TDR-TB
7
) cases make the disease, originally difficult to treat, even more so 
as most drugs in use today are ineffective to treat these mutant strains. Moreover, two billion 
people are estimated to be latently infected with MTB, and 10% of them reactivate to active TB 
with major risk relative to immigrants from endemic areas, people with HIV-1 infection, and 
individuals with underlying diseases (e.g. silicosis, diabetes mellitus and malignant conditions). 
Treatment, if available, is lengthy, severely toxic and prone to interfere with other therapies such 
as the antiretroviral therapy in the case of TB-HIV co-infected patients.  
The need for new shorter therapeutic regimens and new classes of drugs active against MDR-, 
XDR-, and TDR-TB drives pharmaceutical research to accelerate in the development process of 
new anti-TB drugs. There is an urgent need to develop novel anti-tubercular agents with 
alternative mechanisms of action to control TB, one of the leading causes of mortality due to a 
single infectious agent.  
About fifteen years ago, the pyrrole compound 1 (BM212)
8
 was discovered to be a potent anti-
mycobacterial agent. In an effort to identify new pyrrole analogues with improved solubility and 
 ability to kill MDR and XDR mycobacteria, many derivatives of 1 were designed and 
synthesized.
8-10
 Congeners of 1 showed a micromolar activity toward MTB H37Rv. However, 
the first series of analogues (including 1 itself) suffered from poor pharmacokinetic parameters 
(in terms of clearance and microsomal stability) and significant cytotoxicity. Although the most 
recent derivatives showed an improved pharmacokinetics and cytotoxicity profile, their 
physicochemical parameters (such as lipophilicity and aromaticity) need further optimization.
11
 
Genetic analyses of spontaneous mutants resistant to 1 led to the identification of its cellular 
target as the trehalose monomycolate exporter, MmpL3 protein (Rv0206c), member of MmpL 
(Mycobacterial membrane protein Large) family and a validated drug target in MTB.
12 
This 
family has primary structure homology to the resistance-nodulation-cell division (RND) protein 
family, mainly involved in drug resistance in Gram-negative bacteria.
11
 Although the MTB 
genome encodes 13 members of the MmpL family, their function has not been clearly elucidated. 
Despite their annotation as multi-drug transporters, they do not contribute to anti-mycobacterial 
drug resistance.
13
 MmpL3 has also been implicated in heme acquisition by MTB, although it 
might not be its primary role in an endogenous environment.  
Adamantane-diamine compound 2 (SQ109)
 14 
was described as an anti-tubercular drug which is 
active against susceptible and drug resistant MTB strains. Compound 2 exhibited promising 
activity in drug combination during animal preclinical studies
15
 but also experienced poor 
pharmacokinetic parameters.
16
 Diamine 2 is currently undergoing phase 2 clinical trials for 
further development.
17
 Anti-mycobacterial activity of both 1 and 2 was demonstrated to derive 
from targeting the MmpL3 protein.
12
 Given the ability of 1 and 2 to act as anti-mycobacterial 
agents through a common molecular target, we pursued the hypothesis that they could share 
common molecular portions. 
 By means of an in silico molecular modelling approach, the three-dimensional structure of both 
compounds was studied. Although the apparent structural dissimilarity between the two 
compounds, a rough comparison of the molecular structures of 1 and 2 showed an unexpected 
similarity of the topological distribution of their chemical features (Figure 1). In fact, apart from 
the terminal adamantyl moiety of 2 and the p-Cl phenyl ring at the C5 position of 1, the 
remaining part of the structure of 2 was superposable to that of 1. 
On the basis of this similarity, we chose to apply a molecular hybridization approach to design 
new putative anti-mycobacterial compounds. 
The molecular hybridization approach is one of the strategies included within the rational design 
protocol for identification of new biologically relevant small molecules. This approach is based 
on the recognition of structurally comparable or similar molecular portions of two or more 
bioactive compounds. By means of merging of these molecular portions, new hybrid chemical 
entities that maintain structural elements of the parent compounds could be designed. In this 
study, we have chosen the more rigid scaffold of 1 as the template, and to adjust it upon 
comparison with the flexible structure of 2. As a result, the N-(substituted)phenyl pyrrole core of 
1 with a piperazinyl-methyl side chain at position C3 was maintained, while the second phenyl 
substituent at position C5 of 1 was deleted from the new hybrid compounds. In addition, the 
adamantyl moiety present in 2 was inserted as the terminal group bound to N4 of the piperazine 
ring leading to the design of the hybrid compound A (Figure 1).  
Hence, we designed, synthesised and biologically evaluated a set of novel pyrrole derivatives 
with general structure A that are hybrid compounds of the anti-tubercular agents 1 and 2. To 
explore the chemical space around the C3 piperazino-methyl moiety of the new compounds, the 
 distal piperazine nitrogen is substituted with different bulky R
2
 moieties, such as adamantyl, 
norbornyl, cyclohexyl, or aryl groups. Moreover the role of the substituent on C5 and its 
importance for the anti-tubercular activity was explored. According to our superposition 
hypothesis, the aryl moiety at C5 of 1 was replaced by a methyl substituent, thus leading to 
design a library of 2,5-dimethylpyrroles. In addition, a second series of simplified derivatives B 
was also designed through molecular simplification in order to evaluate the influence of the 
piperazine ring on the anti-tubercular activity. Within this series, also according to previous 
works,
18-19
 the piperazine ring was removed from the structure and replaced with a secondary 
amine (or hydroxylamine) at C3. In both cases, the methyl substituent at C2 and C5, as well as 
the N1 aryl groups were left unchanged. 
RESULTS  
Computational design and hypothesis on the common chemical features shared by 1 and 
2: To confirm the superposition pattern above described for 1 and 2, the Phase software
20
 was 
used to find the three-dimensional arrangements of the common chemical portions shared by the 
two compounds (thereafter referred to as common feature models or superposition models). As a 
result, a four-feature representation was obtained, comprised of two hydrophobic groups and two 
protonable atoms (Figure 2). In detail, the p-Cl group at the N1 position of the pyrrole ring of 1 
and one of the terminal methyl group of 2 matched one of the common hydrophobic regions 
(H6). The central methyl group of 2 and the 2-methyl group of 1 corresponded to the second 
hydrophobic portion (H4). On the other hand, the two positively ionizable features (P7 and P8) 
accommodated the two basic nitrogen atoms of both compounds.  
 It is important to point out that this representation of the common chemical features of 1 and 2 
showed two protonable sites that are chemically unrealistic at neutral pH. However, this 
qualitative model only accounts for the presence of the two piperazine nitrogens of 1 and for the 
two amine nitrogens of 2, while it does not take into consideration the mutual influence of the 
two amines during the protonation steps. This limitation was eliminated in a second generation, 
optimized common feature model that is characterized by only one protonable group (Figure 3). 
Analysis of the superposition pattern of 1 and 2 prompted us to omit the aromatic portion at 
position 5 of 1. In fact, a visual inspection of the superposed structures of 1 and 2 showed that 
this moiety does not match an analogous group on 2 (Figure 2), and, consequently, it does not 
represent a common feature of both compounds. Moreover, since the three aromatic rings forced 
the structure of these compounds toward planarity, the removal of one or more of them could be 
in principle profitable for better solubility and bioavailability. In addition, given the well-
established relationship between late stage drug development problems (i.e., the high attrition 
rate of compounds entering the clinical phase) and lipophilicity of compounds,
21-22
 modulation of 
lipophilicity should be taken into account when new putative anti-mycobacterial compounds are 
designed. In addition, since the terminal methyl group of 1 is partially superposed to the 
adamantyl moiety of 2, a hydrophobic group at this position was maintained. Following these 
suggestions and taking into account the similarity between 1 and 2, a new class of pyrrole 
derivatives was designed on the basis of the molecular hybridization routine with the aim of 
obtaining new putative anti-mycobacterial compounds. 
The rigid scaffold of 1 was thus chosen as the template for the design of novel antitubercular 
compounds, and this choice was mainly based on the fact that our research group is well 
 experienced in the synthesis of pyrrole compounds. Moreover, the adamantyl group already 
found in 2 was introduced on the piperazine ring, while the 5-phenyl ring of 1 was removed. 
Chemistry: Synthesis of derivatives with general structure A. A library of pyrrole derivatives 
bearing an N-substituted piperazino-methyl chain at C3 was first synthesized according to 
classical synthetic procedures. Pyrroles 3a-e were synthesized through a microwave-assisted 
Paal-Knorr reaction starting from the appropriate diones and different anilines.
18, 23-24
 Despite 
computational studies suggested to keep a p-Cl moiety fixed on the N1 aryl group, a number of 
different substituents was also introduced to evaluate their steric and electronic effects on the 
anti-mycobacterial activity and to deduce SAR considerations. Pyrroles 3a-e were then coupled 
with differently substituted piperazines in the presence of formaldehyde to afford desired 
pyrroles 7a-m (Table 1). Different bulky substituents were introduced on the piperazine ring to 
explore the chemical space around the pyrrole nucleus. The piperazines 6c-e (cyclohexyl-
piperazine 6c, phenyl-piperazine 6d, 1-adamantyl-piperazine 6e) are commercially available and 
were coupled with 3a-e as purchased. The piperazines 6a-b were synthesized as described in 
Scheme 1 and then reacted with the pyrroles 3a-e. The Boc-piperazine 4 and the appropriate 
ketones 5a-b (2-adamantanone 5a, 2-norbornanone 5b) were reacted in the presence of the 
reducing agent Na(OAc)3BH to yield the corresponding alkylpiperazine intermediates, which 
were immediately converted into the desired piperazines 6a-b by TFA-mediated Boc-cleavage. 
Piperazines 6a-e and pyrroles 3a-e were then coupled via Mannich reaction to afford pyrroles 
7a-m (Table 1). 
Synthesis of derivative with general structure B. A second series of pyrrole derivatives with 
general structure B was synthesised as described in Scheme 2. Pyrrole 3a-c were formylated 
through Vilsmeir-Haack reaction affording the aldehydes 8a-c. The latter compounds were 
 reacted with different primary amines in the presence of Na(AcO)3BH to yield pyrroles 9a-j. 
Moreover, aldehydes 8a-b were reacted with benzylhydroxylamine to afford oximes 10a-b
18
 
which, after treatment with NaCNBH3, led to the corresponding hydroxylamines 11a-b in 
excellent yields. 
Biology: All the compounds were tested for their biological activity by determining the 
minimum inhibitory concentrations (MIC) against a panel of fast-growing environmental and 
slow-growing mycobacterial species and clinical isolates (Table 3 and 4). This included the fast-
growing non-pathogenic strains of M. smegmatis and relatively fast-growing intracellularly 
surviving M. aurum
25
 followed by the vaccine strain M. bovis BCG, the non-pathogenic M. 
tuberculosis mc
2
7000, and finally the pathogenic M. tuberculosis H37Rv. Furthermore, we also 
tested the activity of these compounds against MDR-TB clinical isolates. In addition, 
cytotoxicity analysis was carried out. The eukaryotic cell toxicity of each compound was tested 
against murine macrophage RAW264.7 cells and human monocyte-derived THP-1 cell line to 
ascertain the 50% growth inhibitory concentration (GIC50). Mouse models are routinely used for 
testing the efficacy of both anti-tubercular drugs and vaccines and are considered a highly 
appropriate model. In particular, RAW264.7 are differentiated macrophage cells capable of 
eliciting a whole host of inflammatory responses and been studied and characterised in great 
detail over many decades.
26
 The ratio of the MIC observed against MTB H37Rv and the GIC50 
values provided the selectivity index (SI), or the therapeutic window offered by these molecules. 
It must to be brought to note that there are differences in the assay methods to determine the 
inhibitory concentrations of the compounds against the bacterial pathogen and the eukaryotic 
cells. However, these methods have been extensively standardised so as to reduce ambiguity in 
inferring the selectivity index from these assays. Finally, the effect of these compounds on the 
 efflux pump activity of the model surrogate organism M. aurum was also tested (Table 5).
27
 
Efflux pumps are transport proteins involved in the extrusion of toxic substrates, including 
virtually all classes of anti-mycobacterial drugs, from within cells into the external environment. 
Pumps may be specific for one substrate or may transport a range of structurally dissimilar 
compounds and can be associated with MDR in MTB. Thus, the identification of efflux pump 
inhibitors can lead to new anti-tubercular agents able to reverse drug resistance in TB and to be 
used in combination therapy together with first line drugs. 
DISCUSSION  
We first analysed the data arising from the screening on non-pathogenic M. tuberculosis 
mc
2
7000 (Table 4). In agreement with our initial hypothesis, the insertion of a 1- and a 2-
adamantyl-piperazine group in place of the N-methylpiperazine of 1 led to 7l and 7k with 
significantly contrasting activity. In fact, 7k, bearing the same 2-adamantyl group found in 2, 
was inactive (MIC value > 64 g/mL). On the contrary, the corresponding 1-adamantyl analogue 
7l showed a strong ability to inhibit MTB mc
2
7000 growth, with a MIC value of about 0.5 
g/mL. Compound 7l was then chosen as the most representative compound to be further studied 
for deducing SAR considerations on the new class of hybrid compounds on MTB mc
2
7000. In 
particular, according to the suggestions derived from the superposition pattern between 1 and 2, 
the p-Cl phenyl moiety at C5 of 7l was simplified to a methyl group, leading to 7i with a 
significant 16-fold drop in activity (8.0 g/mL). The corresponding 2-adamantyl analogue 7a 
showed a slight increase in activity (3.3 g/mL). Moreover, small changes in substituents and 
substitution pattern at its 1-phenyl ring clearly showed that small substituents (isopropyl and 
fluorine) at para and ortho positions (such as in 7c and 7b) guaranteed activity retention or 
 enhancement (3.3 and 1.0 g/mL, respectively). Differently, a m-methyl group as in 7d caused a 
significant drop in activity (32 g/mL), in agreement with that previously found for derivatives 
of 1.
8
 Decreasing the bulkiness of the hydrophobic moiety on the piperazine ring from an 
adamantyl (such as in 7i or 7a) to a norbornane group led to a slight improvement of activity 
(MIC of 7g was 2.0 g/mL). On the contrary, a further simplification to a cyclohexyl ring (7h) 
and its aromatization to a phenyl ring (7e) further reduced activity to 8.0 and 32 g/mL, 
respectively. Introduction of a second p-Cl phenyl moiety at C5 of 7e restored a 1.0 g/mL 
activity in 7j. SAR considerations on both 7j and 7e (1.0 and 32 g/mL, respectively) suggested 
that in several cases the presence of the p-Cl phenyl moiety at C5 could improve anti-
mycobacterial activity. On the other hand, a comparison between activity of 7e and its adamantyl 
analogues 7i and 7a (8.0 and 3.3 g/mL, respectively) clearly showed that the p-Cl phenyl 
moiety at C5 was not mandatory for obtaining active compounds, as suggested by the common 
feature model. Also the comparison of the biological profiles of the norbornyl derivatives 7g and 
7m clearly shows that the p-Cl phenyl moiety at C5 in 7m is detrimental for the anti-tubercular 
activity. Moreover, the comparable anti-mycobacterial activities of 7j and 7l (1.0 and 0.5 g/mL, 
respectively) allowed us to hypothesize that the distal nitrogen atom of the piperazine ring (that 
is protonatable in 7l, while has an anilino character in 7j) could be unimportant for activity. This 
result was in agreement with previous pharmacophoric-based calculations and in vitro activity of 
piperidine analogues of 1.
9
 To validate this hypothesis, compounds with a linear amino spacer 
instead of the piperazine ring were synthesized. Among them, 9a had an overall size comparable 
to that of 7e and lacked the distal nitrogen atom of the parent piperazine ring. Its activity was 8-
fold better than that of the piperazine analogue 7e (4.0 and 32 g/mL, respectively). Attempts to 
modify the phenylethylamino side chain of 9a by introduction of an oxygen atom (as in 11a and 
 11b) or by partial rigidification into an aryloxime (as in 10a) led to inactive compounds (>64 
g/mL). Alternatively, shortening the phenylethylamino spacer led to very active compounds. As 
an example, the benzylamino analogue 9b showed a 0.5 g/mL MIC value. Decoration of the 
para position of the terminal phenyl ring with small substituents (such as a F, Cl, and Me) led to 
9g, 9f, and 9e with comparable or slightly lower activity (0.7, 2.0, and 2.0 g/mL, respectively), 
further confirming that the distal nitrogen atom of the piperazine ring was not necessarily 
required for anti-mycobacterial activity of the new hybrid compounds. On the contrary, 
replacement of the p-Cl of 9b with a p-F group as in 9h caused an 8-fold drop in activity (from 
0.5 to 4.0 g/mL). A further reduction of the amino side chain length to a cyclohexylamino and 
to the bulky 2-adamantylamino moiety as in 9c and 9d, respectively, also maintained a 0.5 and 
1.0 g/mL activity. Interestingly, when the methyl group at C5 of compounds 9b and 9c was 
replaced with a p-Cl phenyl moiety leading to derivatives 9i and 9j, a significant drop in activity 
was observed (16 and 8 g/mL respectively). Compounds 9b-c proved to be much more active 
than 1 against MTB mc
2
7000. These latter data confirm the initial hypothesis that an aryl 
substituent at C5, such in 1, is not mandatory to obtain derivatives active against M. tuberculosis. 
Also the new compounds bearing a secondary amine show a better activity profile than 2, thus 
pointing out that a diamine backbone could be not essential for antitubercular activity. 
The same compounds were also assayed on additional mycobacterial strains. Activity against 
the pathogenic MTB H37Rv (Table 4) followed the same trend already shown for the MTB 
mc
2
7000 strain. The only exceptions were represented by 9f and 9g that were inactive or weakly 
active toward MTB H37Rv (16 and >125 g/mL, respectively), while their congener compounds 
9e and 9b showed a 1.0 and 0.5 g/mL activity. The hybrid compounds 7a-b, 7e and 7h showed 
 a good profile with MIC = 7.8 and 3.9 g/mL. The derivative 7j bearing a p-Cl-phenyl 
substituent at C5 showed an improved biological profile (1.9 g/mL). On the other hand, the 
simplified compounds 9 showed higher activity against MTB H37Rv than derivatives 7. In 
particular, compounds 9b and 9c proved to be very active showing again activity (0.5 and 0.2 
g/mL respectively) comparable or better than 1 and 2. 
Moreover, as a general trend, the hybrid compounds showed weak activity toward M. 
smegmatis mc
2
155 (MIC values ranging from 4.0 to >64 g/mL, with only two compounds 
showing better activity – 3.3 and 2.0 g/mL, respectively). Table 3. Similarly, M. aurum was 
scarcely sensitive to the test compounds: only four compounds (namely, 9b, 9e, 9f, and 9g) 
showed a MIC value of about 2.0 g/mL (Table 3). As the whole genome sequence of M. aurum 
has been published recently, comparative genomic analyses of these transporter proteins should 
elucidate why the difference in their drug susceptibilities is observed.
25
 In general, fast growing 
mycobacteria (M. aurum and M. smegmatis) were inhibited at higher concentration than other 
strains. A better anti-mycobacterial activity profile was found toward M. bovis BCG (Table 3), 
with ten compounds showing activity value in the range below 4.0 g/mL and three compounds 
(namely, 9b, 9c, and 9g) with a MIC value of 0.5 g/mL. Among MDR-TB strains (Table 4), 
MDR2 was poorly sensitive to the test compounds, with the only exception of 9a and 9b which 
showed a good activity at 7.8 g/mL and 3.9 g/mL. On the other hand, MDR1 growth was 
blocked by at least 7 compounds with MIC values lower than 4.0 g/mL. Of particular interest 
were compounds 9b and 9c that showed MIC values of about 1.0 and 0.5 g/mL, respectively, 
much better than that of the parent compound 1 and isoniazid. 
 An analysis of anti-mycobacterial data clearly showed that the best compounds (9a, 9b, and 
9c) were characterized by structural features significantly different from those of the parent 
compound 1. In particular, they lacked both the second aryl moiety at the position C5 of the 
pyrrole nucleus and the distal nitrogen atom of the original piperazine ring. Moreover, the overall 
activity underwent an improvement when the basic linear side chain was shortened from the 
phenylethylamino of 9a, to the benzylamino of 9b, to the cyclohexylamino of 9c. 
The C5 aryl moiety was not a mandatory substituent for active compounds, and small groups 
are allowed as decoration of the N1-phenyl ring. A bulky terminal group, such as an adamantane 
and a norbornane, improve the activity of piperazine analogues, while a significant gain of anti-
mycobacterial activity resulted from piperazine replacement by linear aryl and alkylamino side 
chains. 
The high anti-mycobacterial activity maintained even after a significant structural 
simplification of 1,5-diarylpyrroles (derivatives and analogues of 1) into the corresponding 1-
aryl hybrid analogues could be accounted by a comparison of the original pharmacophoric model 
for anti-mycobacterial compounds belonging to the pyrrole class of 1
8
 with the simplified 
common feature model described here. In fact, the original pharmacophoric model
8
 was able to 
accommodate 1 and its derivatives in two different orientations, rotated of about 180 degrees 
around the pyrrole plane. Following this, the aryl moieties at positions N1 and C5 of 1 could 
reciprocally change their spatial location and, consequently, match with the pharmacophore. 
These results suggested that the pharmacophoric portions able to accommodate the substituents 
at positions N1 and C5 are redundant and could be simplified, as also suggested by the 
superposition between 1 and 2. 
 In a further attempt to codify the structural features of the new hybrid pyrroles, a second 
generation common feature model was built starting from a larger set of compounds, comprised 
of 1, 2, and the most active pyrroles (with MIC values  1.0 g/mL). The improved model 
(Figure 3) showed that the distal nitrogen of the piperazine ring of 1 (corresponding to P8 in the 
previous common feature model) was omitted, while an additional hydrophobic region (H2), 
adjacent to the P7 feature (a positively ionizable feature), accommodated the terminal 
hydrophobic groups of the C3 side chain. 
In order to prove the effectiveness of our compounds, the cytotoxicity of the novel pyrroles 
was then evaluated on RAW264.7 cells as well as THP-1 cell lines. Compounds 7j, 9c and 9h 
showed an excellent cytotoxicity profile, with a selectivity index (SI) of 92, 50 and 5.6 against 
RAW264.7 and 155, 37 and 28 against THP-1 cells respectively. Both 7j and 9c showed a better 
cytotoxicity profile than 1 against the murine and human cells (Table 4). 
Finally, the effect of pyrroles on the efflux pump inhibitory (EPI) activity of the model 
surrogate organism M. aurum was tested in order to identify compounds able to reverse multi-
drug resistance in TB (Table 5, Figure 4). An efflux pump activity whole cell-based assay has 
been carried out and, as a consequence, the results account for the total activity of the whole 
population of efflux pumps present in the cells. The efflux pump assay revealed that most of 
pyrrole compounds (barring 7k) possess at least low to moderate inhibitory property. However, a 
weak correlation between inhibition of bacterial growth and efflux pump mechanism is observed. 
For example, 9a-c are very efficient in killing mycobacterial cells but only display moderate 
modulatory effect on the pumps. On the other hand, 11b inhibits efflux inhibition at par with the 
control inhibitor Verapamil, but shows almost no effect on the growth of these cells. 
Interestingly, 7c, 7h, 7i, and 7l, bearing a bulky alkyl substituent on the piperazine ring, showed 
 good/excellent inhibitory activity. These findings confer that specific endogenous targets for 
these compounds are still elusive, however indicate that they may have a pleiotropic modes of 
action and potential to reverse anti-microbial resistance. As TB treatment regimens always 
comprise of a combination of complimentary drugs, this off-target effect of the compounds could 
have a positive impact on the effectiveness of drug treatment regimens. Within this context it is 
noteworthy that five compounds (11b, 7c, 7h, 7i, 7l) show a much higher efflux pump inhibitory 
activity than 1 and 2 (Table 5), who are known inhibitors solely of the pump transporter MmpL3. 
In fact, the less potent mycobacterial growth inhibitors showing higher whole-cell efflux 
inhibitory properties may also prove prospective leads in a multi-drug therapy owing to 
synergistic combinations should that arise. Thus, unlike 1 and 2 which show poor EPI activity, 
11b and 7b could be used in combination with standard antitubercular drugs such isoniazid or 
rifampin to reverse multi-drug resistance in tuberculosis. 
CONCLUSIONS 
In conclusion, a library of pyrrole derivatives was successfully synthesized and evaluated for 
their anti-tubercular activity against MTB and MDR-TB clinical isolates. The new pyrroles were 
designed as hybrids of the anti-mycobacterial agents 1 and 2. Five compounds showed anti-
tubercular activity on MTB at ≤1.0 µg/mL, and two of them (9b and 9c) proved to be highly 
active also against MDR-1 TB strains. SAR studies revealed the key features essential for the 
anti-mycobacterial activity. Finally, the potent anti-tubercular derivative 9c showed low 
eukaryotic cell toxicity, turning out to be an excellent lead candidate for preclinical trials. In 
general, compound 9c showed a better drug profile than 1 in terms of activity, cytotoxicity and 
potency toward MDR-TB clinical isolates. The pharmacokinetics parameters of 9b and 9c will 
 be evaluated in due course and compared with those of 1 in order to prove the efficacy of the 
new compounds and to progress toward preclinical trials. 
EXPERIMENTAL SECTION 
Computational details 
The structures of all the molecules were sketched using Maestro
28
 and then subjected to 
LigPrep program to generate high-quality, all-atom 3D structures to be used as the input for next 
calculations. The OPLS_2005 force field was applied, and possible ionization states were 
generated for the structures at pH 72 using Epik. 
Conformers were generated by MacroModel
29
 with the Systematic Pseudo Monte Carlo (a 
systematic torsional sampling protocol) search algorithm, OPLS-2005 force field with implicit 
GB/SA distance-dependent dielectric solvent model (water as the solvent) at cutoff root mean 
square deviation of 0.5 with 1000 steps. All the conformers were subsequently minimized using 
Polak-Ribiere Conjugate Gradient minimization with 5000 iteractions. For each molecule, a 
conformer set with a maximum energy difference of 25 kcal/mol relative to the global energy 
minimum conformer was stored. 
Both 1 and 2 were used to build three-dimensional common feature models comprised of 
chemical features common to the two compounds. Considering the reduced number of 
compounds and the fact that their anti-mycobacterial activity was assayed by different research 
groups with different tests, we chose to apply a common feature hypothesis generation routine, 
instead of building a quantitative model. Phase
20
 software has been applied to generate the 
models. Minimum and maximum number of sites for all the features were set to 4 and 5, 
 respectively. Only the positively ionizable group (P) and the hydrophobic region (H) features 
were used to build a series of hypotheses, while the aromatic ring (R) feature was not further 
considered by the software because it was not present in the structure of 2. The resulting four-
feature hypotheses were constituted by two H and two P features. 
Biology experimental part  
Bacterial strains and growth conditions: The bacterial species used in this study were M. 
smegmatis mc
2
155 (ATCC 700084), M. aurum (ATCC23366), M. bovis BCG Pasteur (ATCC 
35734), M. tuberculosis mc
2
7000,
30-32 
M. tuberculosis H37Rv (ATTC27294), and two MDR-TB 
clinical isolates (MDR1 and MDR2) obtained from Royal Free Hospital NHS Trust, London, 
UK. The cell line utilised for cytotoxicity studies were the murine macrophage cell line 
RAW264.7 (ATCC TIB-71) and the human peripheral blood monocyte-derived cell line THP-1. 
Mycobacterial species were cultured in either Middlebrook 7H9 broth or Middlebrook 7H10 agar 
media supplemented with albumin-dextrose-catalase (ADC) or oleic acid-albumin-dextrose-
catalase (OADC) enrichments, respectively, purchased from BD Biosciences. All reagents were 
purchased from Sigma-Aldrich unless stated otherwise. 
Bacterial growth inhibition assays.  
Anti-mycobacterial activity: HT-SPOTi was used as described previously
33-35 
to assess the 
minimum inhibitory concentrations of the compounds on M. aurum,
27
 M. tuberculosis H37Rv, 
and the MDR strains of the pathogen. Briefly, the assay was conducted in a semi-automated 96 
well plate format. The compounds were dissolved in a suitable solvent to a concentration of 50 
mg/mL and serially diluted (two-fold dilutions). 2 µL of each dilution were dispensed into a well 
of a 96-well plate to which 200 µL of Middlebrook 7H10 agar medium kept at 55 °C 
 supplemented with 0.05% (v/v) glycerol and 10% (v/v) OADC was added. The concentration 
ranges of the compounds used was 500-0.5 µg/mL. A well with no compounds (DMSO only) 
and isoniazid was used as experimental control. To all the plates, a drop (2 µL) of early to mid-
log bacterial culture containing 2x10
3
 colony forming units (CFUs) was spotted in the middle of 
each well and the plates were incubated at 35 or 37 °C depending on the bacterial species and 
incubated till distinct spots were observed in the control wells (this took  4 days in the case of M. 
aurum and 7 days in the case of M. tuberculosis H37Rv and 9 days for its drug resistant clinical 
isolates). The MICs were determined as the lowest concentration of the compound where 
mycobacterial growth was completely inhibited.  
The MIC of the compounds against M. smegmatis mc
2
155, M. bovis BCG, and M. tuberculosis 
mc
2
7000 were calculated by standard MABA (Microplate Alamar Blue assay) as previously 
described.
30
 Briefly, 200 µL of sterile deionized water was added to all outer-perimeter wells of a 
sterile 96-well plate (Corning Incorporated, Corning, NY) to minimize evaporation of the 
medium in the test wells during incubation. The wells in rows B to G in columns 3 to 11 received 
100 µL of 7H9 medium containing 0.2% casamino acids, 24 µg/mL pantothenate and 10% 
OADC (Beckton Dickinson, Sparks, MD). Compounds were added to rows B–G followed by 1:2 
serial dilutions across the plate to column 10, and 100 µL of excess medium was discarded from 
the wells in column 10. The bacterial culture at 0.5 McFarland standard diluted 1:25 (100 µL) 
was added to the wells in rows B to G in columns 2 to 11, where the wells in column 11 served 
as drug-free controls. The plates were sealed with parafilm and were incubated at 37 °C. A 
freshly prepared 1:1 mixture of Alamar Blue (Celltiter-Blue™, Promega Corp, Madison, WI) 
reagent and 10% Tween
®
 80 (50 µL) and re-incubated at 37 °C for 24 h. 
 Eukaryotic cell toxicity and selectivity indices: The cell lines were grown and maintained in 
RPMI-1640 supplemented with 10% FBS incubated at 37°C with 5% CO2 in a humidified 
incubator. For the experiment, 2 µL of the 50 mg/mL stock solution of each compound was 
diluted in 200 µL of RPMI-1640 medium in the first row of a 96-well microplate and two fold 
dilutions were performed along the rows leaving the last one (Row- H) as a solvent control. 100 
µL containing 10
5
 cells/mL of confluent murine macrophage cells (RAW 264.7) or THP-1 cells 
in logarithmic growth phase were added to each well. The plates were incubated at 37 °C in a 
humidified CO2 incubator (5% CO2) for 48 h. Each well was washed twice with 1x PBS, and 170 
µL fresh RPMI-1640 was added to each well followed by 30 µL of 0.01% trypan blue. AS THP-
1 cells are suspension cultures, the plates were centrifuged between the washing steps. After 
overnight incubation, the change in colour was observed and the fluorescence intensity was 
measured at  exc560/ emi590 nm. 
 Assaying whole-cell drug efflux pump inhibition: The assay was modified from previously 
published protocol.
36
 Early log phase cells of M. aurum (OD600 ~ 0.8) were taken and the OD600 
was adjusted to 0.4 by diluting the cells with culture medium. The cells were collected by 
centrifugation and resuspended in equivalent volume 1x PBS. The test samples contained: 4-
6x10
7
 bacteria/mL in PBS, 0.4% glucose (as a source of energy for efflux pumps activity), 0.5 
mg/L ethidium bromide (as a substrate for efflux pumps) and the compounds being tested at 
1/4x-MIC concentrations. Blank samples contained all of the components mentioned above 
except the bacterial suspension, which was replaced with 1x PBS. Verapamil, a known efflux 
pump inhibitor was used as the positive control at a concentration of 125 µg/mL. Compounds 1 
and 2 were also included in the experiment to obtain a comparison between them and the newly 
synthesised compounds with regards to their efflux inhibitory properties. The experiment was 
 performed in a 96-well plate which was placed in a fluorimeter (FLUOstar OPTIMA, BMG 
Labtech, UK) and the instrument was programmed with the following parameters: wavelengths 
of 544 nm and 590 nm for excitation and detection of fluorescence, gain 2200, a temperature of 
37 °C, and a cycle of measurement every minute for a total period of 60 min. The accumulation 
or efflux of ethidium bromide was monitored for the mentioned period on a real-time basis. 
Chemistry - Materials and methods 
1
H NMR and 
13
C NMR spectra were recorded on JEOL Delta-270 or JEOL ECS-400 
spectrometers operating at the frequencies indicated. Chemical shifts (δ) are in ppm, referenced 
to tetramethylsilane. Coupling constants (J) are reported in Hertz and rounded to 0.5 Hz. 
Splitting patterns are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), 
multiplet (m), broad (br) or some combination of them. Infrared spectra were obtained using a 
Durascope diamond ATR system. Mass spectra (HRMS) were recorded at the EPSRC National 
Mass Spectrometry Service Centre on a Thermo Scientific LTQ Orbitrap XL Mass Spectrometer 
using low-resolution ESI or high-resolution nanoESI techniques. The purity of the compounds 
was assessed by reverse-phase liquid chromatography coupled with a mass spectrometer (Agilent 
series 1100 LC/MSD) with a UV detector at k = 254 nm and an electrospray ionization source 
(ESI). HPLC analyses were performed at 0.4 mL/min flow rate and using a binary solvent 
system of 95:5 methyl alcohol/water. All the solvents were of HPLC grade. Mass spectra were 
acquired in positive mode scanning over the mass range of 50–1500. The following ion source 
parameters were used: drying gas flow, 9 mL/min; nebulize pressure, 40 psig; and drying gas 
temperature, 350 ºC. All target compounds possessed a purity of ≥ 95% as verified by HPLC 
analyses. TLC was performed using commercially available pre-coated plates and visualized 
with UV light at 254 nm; K2MnO4 was used to reveal the products. Flash column 
 chromatography was carried out using Fluorochem Davisil 40-63 u 60 Å. All reactions were 
conducted under a nitrogen atmosphere in oven-dried glassware unless stated otherwise. THF 
was distilled under nitrogen from sodium using a benzophenone indicator. Dichloromethane was 
purchased from Aldrich. Acetonitrile was further dried over 4 Å oven-activated molecular sieves 
for 1 h prior to use. Petrol refers to the fraction of light petroleum ether boiling between 40 and 
65 °C. All other solvents and commercially available reagents were used as received.  
Pyrroles 3a-e were synthesised as described in the literature.
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Synthesis of alkyl piperazines 6a-b. General procedure. 
The Boc piperazine 4 (2 mmol) and the appropriate ketone 5 (2 mmol) were dissolved in THF 
(8 mL) and the resulting mixture was stirred for 5 minutes. The reaction was cooled at 0 °C and 
then Na(AcO)3BH (2.4 mmol) and AcOH (2 mmol) were carefully added. The resulting mixture 
was stirred at rt for 16 h. The reaction was quenched with NaOH 1N (20 mL) and the product 
was extracted with AcOEt (3 x 25 mL). The AcOEt extract was dried (MgSO4), and the solvent 
was evaporated to give the crude piperazine derivatives which were filtered through a pad of 
silica gel (eluent AcOEt/petroleum ether 1:1). The filtered compounds were then dissolved in 
DCM (4 mL) and treated with 1 mL TFA. The resulting mixture was stirred at rt for 12 h. The 
solvents were removed and the crude compound was dissolved in AcOEt (10 mL) and washed 
several times with 1N NaOH (20 mL). The organic phase was dried (MgSO4), and the solvent 
was evaporated to yield the crude piperazines 6a-b which were purified by column 
chromatography using petroleum ether/AcOEt 1:1 as eluent.  
 1-(Adamantan-2-yl)piperazine (6a). Tan oil. 
1
H NMR (400 MHz CDCl3) δ 3.31 (m, 4H), 
2.81 (m, 2H), 2.31 (br s, 2H), 2.01-1.94 (m, 4H), 1.76-1.68 (m, 5H), 1.60-1.53 (m, 4H), 1.42-
1.39 (m, 1H), 1.30-1.27 (m, 1H) ppm. LRMS m/z (ES+) m/z: 221 [M+H]
+
 
1-(Bicyclo[2.2.1]heptan-2-yl)piperazine (6b). Tan oil. 
1
H NMR (400 MHz CDCl3) δ 2.88-
2.82 (m, 5H), 2.28 (br s, 3H), 2.20-2.09 (m, 3H), 1.67-1.60 (m, 2H), 1.41-1.39 (m, 1H), 1.28-
1.19 (m, 4H), 0.82-0.79 (m, 1H) ppm. LRMS m/z (ES+) m/z: 181 [M+H]
+
 
Synthesis of pyrrole derivatives 7a-m. General Procedure. 
Following the Mannich reaction, to a stirred solution of an appropriate pyrrole 3a-e (1.5 mmol) 
in acetonitrile (5 mL), a mixture of the appropriate piperazine 6 (1.5 mmol), formaldehyde (1.5 
mmol) (40% in water), and 1.3 mL of acetic acid was added dropwise. After the addition was 
complete, the mixture was stirred at rt for 3 h. The mixture was then treated with a solution of 
sodium hydroxide (20%, w/v) (20 mL) and extracted with AcOEt (10 mL). The organic extracts 
were combined, washed with water, and dried. After removal of solvent, the residue was purified 
by column chromatography, using silica gel and petroleum ether/ethyl acetate (4:1 v/v) as eluent. 
1-(Adamantan-2-yl)-4-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (7a). Rf 0.11 (AcOEt/hexane 1:1). Tan oil. 
1
H NMR (400 MHz CDCl3) δ 
7.41 (d, 2H, J = 8.7 Hz), 7.12 (d, 2H, J = 8.7 Hz), 5.92 (s, 1H), 3.36 (s, 2H), 2.50 (br s, 4H), 
2.05-2.02 (m, 6H), 1.98 (s, 3H), 1.95 (s, 3H), 1.85-1.72 (m, 5H), 1.68-1.62 (m, 5H), 1.37-1.34 
(m, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 137.7, 133.4, 129.7, 129.3, 127.6, 126.8, 115.2, 
108.7, 67.9, 54.4, 53.5, 49.6, 37.9, 37.3, 31.6, 31.4, 29.0, 27.6, 27.4, 22.7, 14.2, 12.9, 11.0 ppm. 
LRMS m/z (ES+) m/z: 439 [M+1]
+
. HRMS (ESI): calcd for C27H37ClN3 (M + H
+
) 438.2671, 
found 438.2664. 
 1-(Adamantan-2-yl)-4-((1-(2-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (7b). Rf 0.15 (AcOEt/hexane 1:1). Tan oil. 
1
H NMR (400 MHz CDCl3) δ 
7.37-7.36 (m, 1H), 7.22-7.17 (m, 3H), 5.95 (s, 1H), 3.36 (s, 2H), 2.59-2.29 (br s, 4H), 2.08-2.03 
(m, 6H), 1.97 (s, 3H), 1.93 (s, 3H), 1.83-1.75 (m, 5H), 1.67-1.62 (m, 5H), 1.36-1.24 (m, 3H) 
ppm. 
13
C NMR (100 MHz CDCl3) δ159.81, 157.31, 130.84, 129.6, 128.06, 127.2, 126.9, 124.5, 
124.4, 116.7, 116.5, 115.3, 108.6, 67.9, 54.6, 53.6, 49.6, 47.0, 39.3, 37.3, 36.3, 31.9, 31.4, 29.04, 
27.6, 27.5, 22.7, 14.2, 12.4, 10.5 ppm. LRMS m/z (ES+) m/z: 422 [M+1]
+
. HRMS (ESI): calcd 
for C27H37FN3 (M + H
+
) 422.2966, found 422.2889. 
1-(Adamantan-2-yl)-4-((1-(4-isopropylphenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (7c). Rf 0.2 (AcOEt/hexane 1:1). Tan oil. 
1
H NMR (400MHz CDCl3) δ 
7.27-7.24 (m, 2H), 7.10-7.04 (m, 2H), 5.91 (s, 1H), 3.46 (s, 2H), 2.97-2.92 (m, 1H), 2.52 (br s, 
4H), 2.06-2.03 (m, 6H), 1.95 (s, 3H), 1.93 (s, 3H), 1.83-1.75 (m, 5H), 1.68-1.62 (m, 5H), 1.29 (s, 
3H), 1.27 (s, 3H), 1.25 (m, 3H) ppm. 
13
C NMR (100MHz CDCl3) 148.2, 136.6, 128.2, 128.1, 
127.9, 127.1, 126.9, 108.0, 67.9, 54.5, 53.4, 50.8, 49.5, 37.9, 37.3, 33.8, 31.6, 31.4, 29.0, 27.6, 
27.4, 24.0, 22.7, 14.2, 12.9, 11.2, 11.0 ppm. LRMS m/z (ES+) m/z: 446 [M+H]
+
. HRMS (ESI): 
calcd for C30H44N3 (M + H
+
) 446.3530, found 446.3523. 
1-(Adamantan-2-yl)-4-((1-(3-methylphenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (7d). Rf 0.17 (AcOEt/hexane 1:1). Tan oil. 
1
H NMR (400MHz CDCl3) δ 
7.32-7.29 (m, 1H), 7.18-7.16 (m, 1H), 6.99-6.95 (m, 2H), 5.91 (s, 1H), 3.39 (s, 2H), 2.53 (br s, 
4H), 2.38 (s, 3H), 2.03 (m, 6H), 1.99 (s, 3H), 1.95 (s, 3H), 1.83-1.75 (m, 5H), 1.68-1.62 (m, 5H), 
1.37-1.34 (m, 3H) ppm. 
13
C NMR (100MHz CDCl3) δ 139.1, 138.9, 129.0, 128.7, 128.3, 127.7, 
125.4, 108.2, 67.9, 54.5, 53.4, 49.5, 41.0, 37.9, 37.3, 31.4, 29.03, 28.5, 27.6, 27.4, 21.3, 12.9, 
 11.0 ppm. LRMS m/z (ES+) m/z: 418 [M+1]
+
. HRMS (ESI): calcd for C28H40N3 (M + H
+
) 
418.3217, found 418.3234. 
1-((1-(4-Chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)-4-phenylpiperazine (7e). Tan 
oil. Rf 0.43 (AcOEt/hexane 1:1). 
1
H NMR (400 MHz CDCl3) δ 7.44 (d, 2H, J = 8 Hz), 7.26 (dd, 
2H, J = 8.7, 7.3 Hz), 7.15 (d, 2H, J = 7 Hz), 6.94 (d, 2H, J = 7 Hz), 6.85 (m, 1H), 5.96 (s, 1H), 
3.45 (s, 2H), 3.23 (m, 4H), 2.66 (m, 4H), 2.02 (s, 3H), 2.00 (s, 3H) ppm. 
13
C NMR (100 MHz 
CDCl3) δ 151.5, 137.6, 133.5, 129.7, 129.3, 129.1, 127.8, 126.8, 119.5, 115.0, 108.6, 54.5, 52.9, 
49.2, 12.9, 11.0 ppm. LRMS m/z (ES+) m/z: 380 [M+1]
+
. HRMS (ESI): calcd for C23H27ClN3 
(M + H
+
) 380.1888, found 380.1884. 
4,4'-((1-(4-Chlorophenyl)-2,5-dimethyl-1H-pyrrole-3,4-diyl)bis(methylene))bis(1-
phenylpiperazine) (7f). Tan oil. Rf 0.25 (AcOEt/hexane 1:1). 
1
H NMR (400 MHz CDCl3) δ 
7.30-7.28 (d, 2H, J = 8.2 Hz), 7.08 (dd, 4H, J = 8.5, 7.6 Hz), 7.01 (d, 2H, J = 8.7 Hz), 6.77 (d, 
4H, J = 8.2 Hz), 6.66 (m, 2H), 3.34 (s, 4H), 3.03 (m, 8H), 2.47 (m, 8H), 1.85 (s, 6H) ppm. 
13
C 
NMR (100 MHz CDCl3) δ 151.5, 137.7, 133.4, 129.8, 129.3, 129.1, 126.5, 119.5, 116.0, 53.0, 
52.8, 11.0 ppm. LRMS m/z (ES+) m/z: 555 [M+1]
+
. HRMS (ESI): calcd for C34H41ClN5 (M + 
H
+
) 554.3045, found 554.3032. 
1-((1S,4R)-Bicyclo[2.2.1]heptan-2-yl)-4-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (7g). Rf 0.15 (AcOEt/hexane 1:1). Tan oil. 
1
H NMR (400 MHz CDCl3) δ 
7.40 (d, 2H, J = 5 Hz), 7.11 (d, 2H, J = 5 Hz), 5.90 (s, 1H), 3.37 (s, 2H), 2.48 (br m, 5H), 2.24-
2.12 (m, 4H), 1.97 (s, 3H), 1.94 (s, 3H), 1.72-1.65 (m, 2H), 1.46 (m, 1H), 1.33-1.22 (m, 5H), 
0.88-0.81 (m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 137.7, 133.4, 129.7, 129.3, 127.6, 126.8, 
115.2, 108.7, 67.9, 54.4, 52.8, 52.7, 39.0, 38.1, 36.8, 35.8, 30.6, 21.1, 12.8, 11.0 ppm. LRMS 
 m/z (ES+) m/z: 398 [M+H]
+
. HRMS (ESI): calcd for C24H33ClN3 (M + H
+
) 398.2358, found 
398.2352. 
1-((1-(4-Chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)-4-cyclohexylpiperazine (7h). 
Tan oil. Rf 0.15 (AcOEt/hexane 1:1). 
1
H NMR (400 MHz CDCl3) δ 7.40 (d, 2H, J = 5 Hz), 7.10 
(d, 2H, J = 5 Hz), 5.89 (s, 1H), 3.37 (s, 2H), 2.60 (br s, 8H), 2.20 (m, 1H), 1.96 (s, 3H), 1.93 (s, 
3H), 1.88-1.86 (m, 2H), 1.77-1.75 (m, 2H), 1.61-1.58 (m, 1H), 1.26-1.11 (m, 5H) ppm. 
13
C NMR 
(100 MHz CDCl3) δ 137.6, 133.5, 129.7, 129.6, 129.3, 127.7, 118.7, 108.7, 63.5, 56.2, 54.3, 
53.0, 48.8, 29.0, 26.3, 25.9, 12.8, 11.0, 10.5 ppm. LRMS m/z (ES+) m/z: 386 [M+H]
+
. HRMS 
(ESI): calcd for C23H33ClN3 (M + H
+
) 386.2358, found 386.2356. 
1-(Adamantan-1-yl)-4-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (7i). Rf 0.10 (AcOEt/hexane 1:1). Tan oil. 
1
H NMR (400 MHz CDCl3) δ 
7.41 (d, 2H, J = 8.7 Hz), 7.10 (d, 2H, J = 8.7 Hz), 5.89 (s, 1H), 3.38 (s, 2H), 2.67 (br s, 4H), 2.50 
(br s, 4H), 2.05 (m, 4H), 1.96 (s, 3H), 1.93 (s, 3H), 1.69-1.59 (m, 11H) ppm. 
13
C NMR (100 
MHz CDCl3) δ 137.7, 133.4, 129.7, 129.8, 129.3, 127.6, 126.8, 115.0, 108.8, 60.4, 56.1, 54.2, 
53.5, 44.0, 38.5, 37.0, 31.6, 29.7, 25.3, 22.7, 20.7, 18.8, 14.1, 11.0 ppm. LRMS m/z (ES+) m/z: 
439 [M+H]
+
. HRMS (ESI): calcd for C27H37ClN3 (M + H
+
) 438.2671, found 438.2680. 
1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-phenylpiperazine (7j). 
White solid, mp 169 ºC. Rf 0.2 (AcOEt 100%). 
1
H NMR (400 MHz CDCl3) δ 7.33 (d, 2H, J = 8.2 
Hz), 7.23 (m, 2H), 7.07 (dd, 4H, J = 16.9, 8.2 Hz), 6.92 (m, 4H), 6.82 (m, 1H), 6.36 (s, 1H), 3.49 
(s, 2H), 3.21 (m, 4H), 2.67 (m, 4H), 2.07 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 151.4, 
137.8, 133.5, 132.0, 131.7, 131.5, 130.3, 129.8, 129.4, 129.1, 128.8, 128.4, 119.7, 116.9, 116.1, 
 111.7, 54.5, 52.9, 49.2, 11.3 ppm. LRMS m/z (ES+) m/z: 477 [M+H]
+
. HRMS (ESI): calcd for 
C28H28Cl2N3 (M + H
+
) 476.1655, found 476.1648. 
1-(Adamantan-2-yl)-4-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-
yl)methyl)piperazine (7k). Yellow solid, mp 197 ºC. Rf 0.35 (AcOEt/MeOH 4:1). 
1
H NMR (400 
MHz CDCl3) δ 7.34-7.32 (d, 2H, J = 4 Hz), 7.10-7.04 (m, 4H), 6.93 (d, 2H, J = 4 Hz), 6.36 (s, 
1H), 3.44 (s, 2H), 2.54 (br s, 4H), 2.05 (s, 3H), 2.03 (m, 4H), 1.84-1.75 (m, 4H), 1.68-1.63 (m, 
4H), 1.38-1.25 (m, 5H), 0.88-0.82 (m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 137.8, 133.4, 
131.9, 131.5, 130.2, 129.8, 129.4, 128.8, 128.3, 117.1, 111.5, 67.9, 54.4, 53.5, 49.6, 37.9, 37.3, 
31.6, 31.4, 29.0, 27.6, 27.4, 22.7, 14.2, 11.2 ppm. LRMS m/z (ES+) m/z: 534 [M+H]
+
. HRMS 
(ESI): calcd for C32H38Cl2N3 (M + H
+
) 534.2437, found 534.2425. 
1-(Adamantan-1-yl)-4-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-
yl)methyl)piperazine (7l). Yellow solid, mp 148 ºC. Rf 0.34 (AcOEt/MeOH 4:1). 
1
H NMR (400 
MHz CDCl3) δ 7.34-7.32 (m, 2H), 7.10-7.03 (m, 4H), 5.92 (s, 1H), 6.91 (m, 2H), 6.33 (s, 1H), 
3.48 (s, 2H), 2.72-2.70 (br d, 8H), 2.07-2.02 (m, 4H), 2.04 (s, 3H), 1.71-1.56 (m, 11H) ppm. 
13
C 
NMR (100 MHz CDCl3) δ 137.8, 133.4, 131.6, 131.5, 130.3, 129.7, 129.4, 128.8, 128.3, 125.1, 
116.5, 111.9, 66.6, 54.1, 53.2, 44.0, 38.3, 36.9, 32.2, 29.7, 26.4, 23.5, 18.7, 13.2, 11.3 ppm. 
LRMS m/z (ES+) m/z: 535 [M+H]
+
. HRMS (ESI): calcd for C32H38Cl2N3 (M + H
+
) 534.2437, 
found 534.2424. 
1-(Bicyclo[2.2.1]heptan-2-yl)-4-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-
yl)methyl)piperazine (7m). Pale yellow solid, mp 81 ºC. Rf 0.40 (AcOEt/MeOH 4:1). 
1
H NMR 
(400 MHz CDCl3) δ 7.26 (d, 2H, J = 12 Hz), 7.04 (d, 2H, J = 12 Hz), 6.99 (d, 2H, J = 12 Hz), 
6.85 (d, 2H, J = 12 Hz), 6.30 (s, 1H), 3.44 (s, 2H), 2.51 (brs, 6H), 2.19-2.17 (m, 2H), 2.12-2.07 
 (m, 1H), 2.00 (s, 3H), 1.66-1.62 (m, 2H), 1.43-1.40 (m, 1H), 1.29-1.17 (m, 7H) ppm. 
13
C NMR 
(100 MHz CDCl3) δ 137.8, 133.4, 131.9,131.5, 129.7, 128.7, 128.3, 111.8, 67.9, 65.9, 54.2, 52.6, 
38.9, 38.0, 36.8, 36.8, 31.6, 30.6, 22.7, 21.0, 14.2, 11.2 ppm. LRMS m/z (ES+) m/z: 494 
[M+H]
+
. HRMS (ESI): calcd for C29H34Cl2N3 (M + H
+
) 494.2124, found 494.2113. 
Synthesis of compounds 8a-c. General procedure. 
POCl3 (6 mmol) was added dropwise to a round bottom flask containing ice-cooled DMF (5 mL) 
under N2 atmosphere. After 15 min, a solution of the appropriate pyrrole 3a-b and 3e (1 mmol) 
was added to the stirring solution. Then the reaction mixture was allowed to stir at 100 ºC for 3 
h. The reaction was monitored through TLC. After completion, the reaction was quenched with 
10% w/v NaOH solution (20 mL). The reaction mixture was then diluted with EtOAc (10 mL), 
washed two times with EtOAc (10 mL) and once with brine (20 mL). The organic extracts were 
collected and then they were dried over MgSO4, filtered and concentrated under reduced 
pressure. The residue was then purified by flash chromatography (hexanes-AcOEt, 4:1 v/v) 
affording the desired compounds 8a-c. 
1-(4-Chlorophenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde (8a). Tan oil. Rf 0.67 
(hexane/AcOEt 9:1). 
1
H NMR (400 MHz CDCl3) δ 9.71 (s, 1H), 7.41-7.39 (d, 2H, J =7.8), 7.10-
7.07 (d, 2H, J =7.8), 6.25 (s, 1H), 2.17 (s, 3H), 1.88 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 
185.3, 162.6, 138.7, 135.5, 130.9, 129.6, 129.3, 122.1, 106.15, 12.7, 11.2 ppm. Data are in 
agreement with those previously reported.
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1-(4-Fluorophenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde (8b). Tan oil. Rf 0.71 
(hexane/AcOEt 9:1). 
1
H NMR (400 MHz CDCl3) δ 9.86 (s, 1H), 7.20-7.17 (m, 4H), 6.36 (s, 1H), 
 2.26 (s, 3H), 1.96 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 187.3, 129.8, 120.4, 117.2, 116.8, 
116.6, 105.9, 12.7, 11.2 ppm. Data are in agreement with those previously reported.
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1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carbaldehyde (8c). White solid, mp 110 
ºC. Rf 0.6 (hexane/AcOEt 1:1). 
1
H NMR (400 MHz CDCl3) δ 9.89 (s, 1H), 7.33 (d, 2H, J = 12 
Hz), 7.09 (d, 2H, J = 12 Hz), 7.01 (d, 2H, J = 12 Hz), 6.87 (d, 2H, J = 12 Hz), 6.70 (s, 1H), 2.32 
(s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 185.6, 140.1, 135.6, 134.5, 133.2, 132.0, 130.0, 
129.8, 129.5, 129.4, 128.6, 122.9, 108.9, 11.5 ppm. LRMS m/z (ES+) m/z: 331 [M+H]
+
.  
Synthesis of pyrrole derivatives 9a-j. General Procedure. 
The appropriate aldehyde 8a-c (1 mmol) was dissolved in 5 mL of THF in a round bottom flask. 
Then AcOH (1 mmol) and the appropriate amine (1 mmol) were added to the stirring solution at 
room temperature. The mixture was allowed to stir at room temperature for 20 minutes before 
NaB(AcO)3H (3 mmol) was added. The mixture was allowed to stir at room temperature for 18h. 
Then, after completion, the reaction was quenched with NaOH 1M solution (25 mL). The 
mixture was then allowed to stir for 30 minutes. The reaction mixture was then diluted with 
EtOAc (10 mL), washed two times with EtOAc (10 mL) and once with brine (20 mL). The 
organic extracts were collected and then dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was then purified by flash chromatography (hexane-AcOEt, 6:4 
v/v) affording the desired compounds 9a-j. 
N-((1-(4-Chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)-2-phenylethan-1-amine 
(9a). Tan oil. Rf 0.29 (AcOEt/hexane 1:1). 
1
H NMR (400 MHz CDCl3) δ 7.42-7.40 (d, 2H, J = 
1.4 Hz), 7.29-7.27 (m, 2H), 7.24-7.22 (m, 3H), 7.12-7.10 (d, 2H, J = 1.4 Hz), 5.90 (s, 1H), 3.63 
(s, 2H), 2.95 (m, 2H), 2.86 (m, 2H), 1.99 (s, 3H), 1.94 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) 
 δ 140.3, 137.6, 133.5, 129.6, 129.3, 128.8, 128.5, 128.0, 126.1, 125.5, 118.1, 107.1, 51.0, 45.7, 
36.4, 12.8, 10.7 ppm. LRMS m/z (ES+) m/z: 339 [M+H]
+
. HRMS (ESI): calcd for C21H24ClN2 
(M + H
+
) 339.1623, found 339.1603. 
N-Benzyl-1-(1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methanamine (9b). Tan oil. 
Rf 0.5 (AcOEt/hexane 1:1). 
1
H NMR (400 MHz CDCl3) δ 7.39 (d, 2H, J = 8.7 Hz), 7.34-7.27 (m, 
4H), 7.22-7.20 (m, 1H), 7.10 (d, 2H, J = 8.7 Hz), 5.92 (s, 1H), 3.83 (s, 2H), 3.60 (s, 2H), 1.97 (s, 
3H), 1.91 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 140.7, 137.6, 133.5, 129.6, 129.3, 128.3, 
128.1, 127.9, 126.8, 125.6, 118.1, 107.1, 53.5, 45.0, 12.8, 10.7 ppm. LRMS m/z (ES+) m/z: 325 
[M+H]
+
. HRMS (ESI): calcd for C20H22ClN2 (M + H
+
) 325.1466, found 325.1466.
 
N-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)cyclohexanamine (9c). Tan 
oil. Rf 0.17 (AcOEt/hexane 1:1). 
1
H NMR (400 MHz CDCl3) δ 7.40 (d, 2H, J = 8.2 Hz), 7.10 (d, 
2H, J = 8.2 Hz), 5.91 (s, 1H), 3.59 (s, 2H), 2.53-2.48 (m, 1H), 1.98 (s, 3H), 1.95 (s, 3H), 1.94-
1.90 (m, 2H), 1.74-1.70 (m, 2H), 1.16-1.06 (m, 3H), 0.85-0.81 (m, 3H) ppm. 
13
C NMR (100 
MHz CDCl3) δ 137.6, 133.4, 129.6, 129.3, 128.0, 125.3, 118.6, 107.0, 56.7, 42.8, 33.6, 26.3, 
25.1, 12.8, 10.7 ppm. LRMS m/z (ES+) m/z: 317 [M+H]
+
. HRMS (ESI): calcd for C19H26ClN2 
(M + H
+
) 317.1779, found 317.1779. 
N-((1-(4-Chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)adamantan-2-amine (9d). 
Tan oil. Rf 0.51 (AcOEt/hexane 1:1). 
1
H NMR (400 MHz CDCl3) δ 7.41 (d, 2H, J = 8.0 Hz), 7.12 
(d, 2H, J = 8.0 Hz), 5.94 (s, 1H), 3.57 (s, 2H), 2.81 (m, 1H), 2.04-2.00 (m, 2H), 1.99 (s, 3H), 
1.97 (s, 3H), 1.93 (m, 2H), 1.86-1.83 (m, 3H), 1.76-1.70 (m, 5H), 1.50-1.47 (m, 2H) ppm. 
13
C 
NMR (100 MHz CDCl3) δ 137.6, 133.4, 129.6, 129.3, 127.9, 125.4, 118.8, 107.2, 61.7, 42.9, 
 38.1, 37.7, 32.1, 31.5, 28.0, 27.8, 12.9, 10.7 ppm. LRMS m/z (ES+) m/z: 369 [M+H]
+
. HRMS 
(ESI): calcd for C23H30ClN2 (M + H
+
) 369.2092, found 369.2089. 
1-(1-(4-Chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-N-(4-methylbenzyl)methanamine 
(9e). Tan oil. Rf 0.37 (AcOEt/MeOH 4:1). 
1
H NMR (400 MHz CDCl3) δ 7.41 (d, J = 8.7 Hz, 
2H), 7.24 (d, J = 7.9 Hz, 2H), 7.13-7.10 (m, 4H), 5.94 (s, 1H), 3.18 (s, 2H), 3.61 (s, 2H), 2.32 (s, 
3H), 1.99 (s, 3H), 1.93 (s, 3H), ppm. 
13
C NMR (100 MHz CDCl3) δ 137.6, 137.4, 136.4, 133.5, 
129.6, 129.4, 129.1, 128.2, 128.0, 125.8, 117.9, 107.2, 53.1, 44.9, 21.2, 12.9, 10.8 ppm. LRMS 
m/z (ES+) m/z: 339 [M+H]
+
. HRMS (ESI): calcd for C21H24ClN2 (M + H
+
) 339.1623, found 
339.1624. 
N-(4-Chlorobenzyl)-1-(1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methanamine 
(9f). Tan oil. Rf 0.12 (AcOEt 100%). 
1
H NMR (400 MHz CDCl3) δ 7.41 (d, J = 8.7 Hz, 2H), 
7.30-7.24 (m, 4H), 7.11 (d, J = 8.2 Hz, 2H), 5.91 (s, 1H), 3.81 (s, 2H), 3.59 (s, 2H), 1.99 (s, 3H), 
1.92 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 139.3, 133.7, 129.6, 129.5, 129.4, 128.4, 128.1, 
125.7, 117.9, 107.1, 52.7, 45.1, 12.8, 10.8 ppm. LRMS m/z (ES+) m/z: 359 [M+H]
+
. HRMS 
(ESI): calcd for C20H21Cl2N2 (M + H
+
) 359.1076, found 359.1076. 
N-(4-Fluorobenzyl)-1-(1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methanamine 
(9g). Tan oil. Rf 0.16 (AcOEt 100%). 
1
H NMR (400 MHz CDCl3) δ 7.41 (d, J= 8.7 Hz, 2H), 7.31 
(dd, J = 8.7 Hz 2H), 7.11 (d, J = 8.2 Hz, 2H), 6.99 (t, J= 8.2 Hz, 2H), 5.91 (s, 1H), 3.81 (s, 2H), 
3.59 (s, 2H), 1.99 (s, 3H), 1.92 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 163.1, 160.7, 137.6, 
133.6, 129.7, 129.6, 129.4, 128.1, 125.7, 118.0, 115.2, 107.1, 52.8, 45.1, 12.8, 10.8 ppm. LRMS 
m/z (ES+) m/z: 343 [M+H]
+
. HRMS (ESI): calcd for C20H21ClFN2 (M + H
+
) 343.1372, found 
343.1374. 
 N-Benzyl-1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methanamine (9h). Tan oil. 
Rf 0.20 (AcOEt/hexane 4:1). 
1
H NMR (400 MHz CDCl3) δ 7.36-7.29 (m, 4H), 7.23 (t, J = 7.9 
Hz, 1H), 7.15-7.09 (m, 4H), 5.92 (s, 1H), 3.85 (s, 2H), 3.61 (s, 2H), 1.98 (s, 3H), 1.91 (s, 3H) 
ppm. 
13
C NMR (100 MHz CDCl3) δ 130.1, 129.9, 128.4, 128.2, 117.9, 116.2, 115.9, 106.8, 53.6, 
45.2, 12.9, 10.8 ppm. LRMS m/z (ES+) m/z: 309 [M+H]
+
. HRMS (ESI): calcd for C20H22FN2 
(M + H
+
) 309.1762, found 309.1764. 
N-Benzyl-1-(1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methanamine (9i). White 
solid, mp 183 ºC. Rf 0.23(AcOEt/MeOH 9:1). 
1
H NMR (400 MHz CDCl3) δ 7.31-7.25 (m, 7H), 
7.04 (d, 2H, J = 12 Hz), 6.97 (d, 2H, J = 12 Hz), 6.86 (d, 2H, J = 12 Hz), 6.31 (s, 1H), 3.82 (s, 
2H), 3.62 (s, 2H), 1.96 (s, 3H), 1.80 (brs, 1H) ppm. 
13
C NMR (100 MHz CDCl3) δ 137.3, 133.9, 
132.7, 132.0, 130.0, 129.6, 129.5, 128.9, 128.3, 111.4, 110.5, 29.1, 24.6, 11.4 ppm. LRMS m/z 
(ES+) m/z: 421 [M+H]
+
. HRMS (ESI): calcd for C25H23Cl2N2 (M + H
+
) 421.1233, found 
421.1228. 
N-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)cyclohexanamine (9j). White 
solid, mp 218 ºC. Rf 0.32(AcOEt/MeOH 9:1). 
1
H NMR (400 MHz CDCl3) δ 7.24 (d, 2H, J = 12 
Hz), 7.00 (d, 2H, J = 12 Hz), 6.95 (d, 2H, J = 12 Hz), 6.80 (d, 2H, J = 12 Hz), 6.69 (s, 1H), 2.93-
2.87 (m, 1H), 2.19 (d, 2H, J = 12 Hz), 2.01 (s, 3H), 1.76-1.63 (m, 3H), 1.21-1.15 (m, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 137.0, 133.9, 132.0, 129.7, 128.9, 128.3, 111.4, 110.5, 55.0, 39.4, 
29.1, 28.9, 24.6, 11.4 ppm. LRMS m/z (ES+) m/z: 413 [M+H]
+
. HRMS (ESI): calcd for 
C24H27Cl2N2 (M + H
+
) 413.1546, found 413.1548. 
Synthesis of oximes 10a-b. General procedure.
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 The appropriate aldehyde 8a-b (1 mmol) was dissolved in 5mL of THF in a round bottom flask. 
Then AcOH (1 mmol) and benzyl-hydroxylamine (1 mmol) were added to the stirring solution at 
room temperature. The mixture was allowed to stir at room temperature for 18h. After 
completion, the reaction was quenched with NaOH 1M solution (25 mL). The reaction mixture 
was then diluted with EtOAc (10 mL), washed two times with EtOAc (10 mL) and once with 
brine (20 mL). The organic extracts were collected and then dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was then purified by flash chromatography 
(hexanes-AcOEt, 6:4 v/v) affording the desired compounds 10a-b. 
1-(4-Chlorophenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde O-benzyl oxime (10a). Tan 
oil. Rf 0.88 (hexane/Et2O 3:2). 
1
H NMR (400 MHz CDCl3) δ 8.15, 7.45-7.41 (m, 4H), 7.37-7.33 
(m, 2H), 7.30-7.29 (m, 1H), 7.11 (d, 2H, J = 8.7 Hz), 6.24 (s, 1H), 5.14 (s, 2H), 2.03 (s, 3H), 
1.97 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 144.6, 138.0, 136.6, 134.3, 130.8, 130.1, 129.7, 
129.6, 128.5, 128.4, 127.8, 112.9, 104.6, 75.9, 12.8, 11.5 ppm. LRMS m/z (ES+) m/z: 339 
[M+H]
+
. HRMS (ESI): calcd for C20H19ClN2O (M + H
+
) 339.1259, found 339.1260. 
Synthesis of compounds 11a-b. General procedure. 
The appropriate oxime 10a-b (1 mmol) was dissolved in 5 mL of THF in a round bottom flask. 
Then, NaBH3(CN) (3 mmol) was added to the solution and the mixture was allowed to stir at 
room temperature for 18h. Then, the reaction was quenched with NaOH 1M solution (25 mL). 
The reaction mixture was then diluted with EtOAc (10 mL), washed two times with EtOAc (10 
mL) and once with brine (20 mL). The organic extracts were collected and then it was dried over 
MgSO4, filtered and concentrated under reduced pressure. The residue was then purified by flash 
chromatography (hexanes-AcOEt, 6:4 v/v) affording the desired compounds 11a-b. 
 O-Benzyl-N-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)hydroxylamine 
(11a). Tan oil. Rf 0.43 (AcOEt/hexane 2:3). 
1
H NMR (400 MHz CDCl3) δ 7.42-7.25 (m, 7H), 
7.10 (d, 2H, J = 8.7 Hz), 5.90 (s, 1H), 5.48 (brs, 1H), 4.74 (s, 2H), 3.91 (s, 2H), 1.97 (s, 3H), 
1.93 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 138.2, 137.5, 133.6, 129.6, 129.4, 128.6, 128.4, 
128.2, 127.3, 126.9, 114.3, 107.6, 76.1, 48.5, 12.8, 10.7 ppm. LRMS m/z (ES+) m/z: 339 [M-
H
+
]. HRMS (ESI): calcd for C20H20ClN2O (M - H
+
) 339.1264, found 339.1259. 
O-Benzyl-N-((1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)hydroxylamine 
(11b). Rf 0.45 (AcOEt/hexane 2:3). Tan oil. 
1
H NMR (400 MHz CDCl3) δ 7.39-7.28 (m, 5H), 
7.12 (m, 4H), 5.90 (s, 1H), 4.75 (s, 2H), 3.92 (s, 2H), 1.96 (s, 3H), 1.92 (s, 3H) ppm. 
13
C NMR 
(100 MHz CDCl3) δ 138.2, 134.9, 130.0, 129.9, 128.6, 128.4, 128.3, 127.8, 127.1, 116.2, 115.9, 
114.0, 107.3, 76.1, 48.5, 12.8, 10.7 ppm. LRMS m/z (ES+) m/z: 323 [M - H
+
]. HRMS (ESI): 
calcd for C20H20FN2O (M - H
+
) 323.1560, found 323.1554. 
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 FIGURES  
Figure 1. Graphical representation (left) of 1 and 2, and rough comparison of the topological 
distribution of their chemical features (middle upper panel), and superposition of their three-
dimensional conformers as generated by the common feature hypothesis generation routine 
(middle lower panel; 1: blue, 2: red). The flexible structure of 2 is well superposable to the 
skeleton of 1. The general structures A and B of the hybrid compounds are also shown (right). 
 Figure 2. Graphical representation of the four-feature superposition model common to 1 (thin 
lines) and 2 (thick lines). The two protonatable chemical features (P7 and P8) are in blue, while 
the two hydrophobic regions (H4 and H6) are in green. The conformer of 1 represented in the 
picture is 0.013 kJ/mol far from the lowest energy conformation, while the energy difference 
between the lowest energy conformation of 2 and the conformer reported in the picture is 4.660 
kJ/mol. 
 
 Figure 3. Graphical representation of the four-feature improved model matched by the most 
active hybrid pyrrole 9c. Changes occurred within the region of space occupied by the C3 side 
chain: the positively ionized P8 feature previously accommodating the N4 nitrogen atom of the 
piperazine was omitted, while an additional hydrophobic region was added, that corresponded to 
the terminal bulky substituent of the C3 side chain. 
 
 SCHEMES  
Scheme 1. Synthesis of pyrroles 3a-e and piperazines 6a-b 
 
 
 
 
 
 
 
Scheme 2. Synthesis of pyrroles 9, 10 and 11 
 
 TABLES.  
Table 1. First series of pyrrole derivatives 7a-l 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
Isolated yields are reported. 
b
Isolated as side product. 
c
Mixture of exo/endo isomers. 
 
 
 
Cmpd R R
1
 X Yield %
a
 
7a Me 4-Cl 2-Adamantyl 56 
7b Me 2-F 2-Adamantyl 45 
7c Me 4-iPr 2-Adamantyl 51 
7d Me 3-Me 2-Adamantyl 48 
7e Me 4-Cl Phenyl 65 
7f
b
 Me 4-Cl Phenyl 35 
7g Me 4-Cl 2-Norbornyl
c
 55 
7h Me 4-Cl Cyclohexyl 52 
7i Me 4-Cl 1-Adamantyl 54 
7j 4-Cl-Phenyl 4-Cl Phenyl 64 
7k 4-Cl-Phenyl 4-Cl 2-Adamantyl 65 
7l 4-Cl-Phenyl 4-Cl 1-Adamantyl 60 
7m 4-Cl-Phenyl 4-Cl 2-Norbornyl
c
 56 
 Table 2. Second series of pyrrole derivatives 
 
Cmpd R
1
 R
2
 R Yield %
a
 
9a Cl Me PhCH2CH2 75 
9b Cl Me PhCH2 79 
9c Cl Me Cyclohexyl 77 
9d Cl Me 2-Adamantyl 60 
9e Cl Me 4-Me-Bn 82 
9f Cl Me 4-Cl-Bn 78 
9g Cl Me 4-F-Bn 80 
9h F Me PhCH2 82 
9i Cl 4-Cl-Phenyl PhCH2 78 
9j Cl 4-Cl-Phenyl Cyclohexyl 75 
10a Cl - - 75 
10b
15
 F - - 78 
11a Cl - - 80 
11b F - - 82 
a
Isolated yields 
 Table 3. Anti-tubercular activity on M. smegmatis, M. bovis BCG and M. aurum mycobacterial 
strains. 
Cmpd 
MIC (g/mL) 
M. smegmatis 
mc
2
155 
M. bovis BCG M. aurum 
7a 8.0 3.3 7.8 
7b 13 1.3 250 
7c 21 4.0 500 
7d 64 62 500 
7e 32 32 31 
7f >64 >64 250 
7g 27 32 16 
7h 27 21 31 
7i 8.0 16 16 
7j >64 2.0 - 
7k >64 64 - 
7l 3.3 2.0 62 
7m 64 64 250 
9a 32 16 16 
9b 4.0 0.5 1.9 
9c 8.0 0.4 7.8 
9d 16 2.0 62 
9e 8.0 4.0 1.9 
9f 4.0 8.0 1.9 
 9g 2.0 0.5 1.9 
9h 16 13 7.8 
9i 8.0 8.0 1.0 
9j 4.0 4.0 1.0 
10a >64 >64 - 
11a >64 >64 - 
11b >64 >64 - 
1 25
8
 0.78
11
 16 
2 4 2 7.8 
‘-’ indicates that no inhibition was seen even at the maximum concentration tested in the 
experiment (125 µg/mL in the case of M. smegmatis and M. bovis BCG and 500 µg/mL in the 
case of M. aurum). All experiments have been performed in triplicate.  
 Table 4. Biological evaluation of the compounds against bacterial and eukaryotic cells. 
Selectivity index (SI) is calculated as the ratio between M. tuberculosis H37Rv MIC and GIC50.  
Cmpd 
M. tuberculosis MIC (g/mL) GIC50 
(µg/mL) 
RAW 
264.7 
GIC50 
(µg/mL) 
THP-1 
SI 
RAW 
264.7 
SI 
THP-1 mc
2
7000 H37Rv MDR1 MDR2 
7a 3.3 7.8 7.8 16 5.7 32 ± 1 0.7 4.1 
7b 1.0 3.9 7.8 16 11 26 ± 1 2.8 6.7 
7c 3.3 16 62 125 92 72 ± 1 5.7 4.5 
7d 32 16 31 125 22 37 ± 1 1.4 2.3 
7e 32 7.8 31 >125 33 25 ± 1 4.2 3.2 
7f >64 31 62 >125 500 113 ± 1 16 3.6 
7g 2.0 1.9 3.9 31 5.6 16 ± 5 2.9 8.4 
7h 8.0 3.9 7.8 62 5.5 16 ± 1 1.4 4.1 
7i 8.0 16 125 125 0.1 16 ± 1 0.006 1.0 
7j 1.0 1.9 3.9 >125 175 294 ± 5 92 155 
7k >64 62 125 125 95 500 ± 10 1.5 8.1 
7l 0.5 7.8 16 62 23 35 ± 18 2.9 4.5 
7m 64 - - - - 429 - 6.7 
9a 4.0 1.0 1.9 7.8 9.9 7.3 ± 2.7 10 7.3 
9b 0.5 0.5 1.0 3.9 5.5 7.2 ± 3.7 11 14 
9c 0.5 0.2 0.5 16 10 7.4 ± 1.4 50 37 
9d 1.0 1.9 3.9 125 19 15 ± 10 10 7.8 
9e 2.0 1.0 3.9 7.8 0.1 6.1 ± 2.1 0.1 6.1 
9f 2.0 16 31 >125 0.1 18 ± 1 0.006 1.1 
 9g 0.7 >125 - 16 26 8.4 ± 1.7   
9h 4.0 1.0 7.8 62 5.6 28 ± 1 5.6 28 
9i 16 - - - - 99 ± 1 - 6.1 
9j 8 - - - - 3.9 - 0.5 
10a >64 >125 >125 >125 128 500 ± 22 1 <4 
10b - 25
15
 - - -  - - 
11a >64 - 125 - 133 67 ± 1 - - 
11b >64 >125 62 >125 123 292 ± 41 1 <2.3 
1 8 1.0 3.9 16 19 3.23
11
 19 3.23 
2 2 0.51
15
 ND ND ND - ND ND 
INH - 0.24 10 25 ND - ND - 
ND: not determined. ‘-’ indicates that no inhibition was seen even at the maximum 
concentration tested in the experiment (125 µg/mL in the case of M. tuberculosis variants). 
Isoniazid (INH) was used as drug control. All experiments have been performed in triplicate.  
 
 Figure 4. Graphs showing the accumulation of ethidium bromide (EtBr) within M. aurum cells 
in the presence of selected compounds and positive (Verapamil) and negative (1x PBS) controls. 
Low to very high inhibition of efflux (as a representation of increased level of EtBr 
accumulation) are shown by the numbers 1-4. The experiments were performed in triplicate 
(n=3) and the graph is plotted using the average values obtained.  
 
 
 
 
 
 
 
 
 
 
 
 Table 5. Efflux pump inhibitory (EPI) activity.  
Cmpd 
EPI 
M. aurum 
Cmpd 
EPI 
M. aurum 
Cmpd 
EPI 
M. aurum 
7a 1 7k 0 9h 1 
7b 1 7l 3 9i 1 
7c 3 7m ND 9j 2 
7d 2 9a 2 10a 1 
7e 1 9b 2 10b ND 
7f 2 9c 2 11a 2 
7g 1 9d 1 11b 4 
7h 4 9e 2 1 2 
7i 4 9f 2 2 2 
7j 2 9g 1 INH ND 
Efflux pump inhibitory (EPI) activity of the compounds is marked from 0-4 wherein: 0 refers to 
no inhibition, 1-low inhibition (efflux substrate accumulation above cell control to 20,000 
relative fluorescence units), 2-moderate inhibition (efflux substrate accumulation between 20-
30,000 units), 3-high inhibition (efflux substrate accumulation between 30-40,000 units), 4-very 
high inhibition (efflux substrate accumulation between 40-50,000 units). ND: not determined. 
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